Business Context and Reporting Period
This Form 10-Q covers Celsion Corporation for the quarterly period ended December 31, 2001. The company is a clinical-stage biotechnology firm focused on developing thermotherapy systems and heat-activated liposomes. It has incurred substantial operating losses since inception and currently generates no product revenue, as its new technologies are undergoing pivotal Phase II clinical trials and await FDA approval.
Key Financial Metrics
| Metric | Q3 2002 (Ended Dec 31, 2001) | Q3 2001 (Ended Dec 31, 2000) |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(1,653,408) | $(1,374,452) |
| Operating Expenses | $1,664,468 | $1,486,975 |
| Cash and Cash Equivalents | $4,335,194 | $7,480,990 (End of period prior year) |
| Working Capital | $4,456,592 | $2,388,900 (As of Sept 30, 2001) |
| Accumulated Deficit | $(35,281,516) | Not stated for prior period |
| Net Cash Used in Operating Activities | $(1,882,049) | $(1,279,557) |
| Net Cash Provided by Financing Activities | $3,711,158 | $0 |
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses increased by $177,493 (12%) to $1.66 million. This was driven by a 102% increase in Research and Development (R&D) expenses to $1.12 million, offset by a 42% decrease in Selling, General, and Administrative (SG&A) expenses to $541,247.
- R&D Allocation: The increase in R&D and decrease in SG&A were primarily due to the reallocation of general expenses (rent, utilities) between the two categories, alongside increased costs for Benign Prostatic Hyperplasia (BPH) clinical trials and engineering.
- Liquidity: Cash and cash equivalents increased significantly from $2.51 million at the end of the prior quarter (Sept 30, 2001) to $4.34 million, resulting from a private placement of equity securities.
- Net Loss: The net loss widened to $1.65 million from $1.37 million in the comparable prior year period.
Guidance, Outlook, and Risks
- Outlook: The company expects to continue incurring operating losses for the foreseeable future. It anticipates expending approximately $7.5 million for the remainder of fiscal year 2002 on R&D and administration.
- Capital Needs: The company has no committed sources of additional financing. It expects to meet funding needs through current resources and a private placement completed on January 9, 2002. Failure to secure additional capital could force the company to delay or scale back operations.
- Clinical Progress: The company is completing BPH Phase II trials and intends to accelerate Phase II breast cancer trials. It plans to submit Investigational New Drug (IND) applications for Doxorubicin-laden heat-activated liposomes.
- Legal Contingency: A significant legal dispute with former director Warren C. Stearns was settled in January 2002. The settlement requires the company to pay up to $265,000 in legal fees and issue warrants to purchase 6.3 million shares at $0.01 per share.
- Risks: Key risks include the inability to obtain regulatory approvals, the slow development of the thermotherapy market, and the dependence on equity financing.
Investor Verification Checklist
- Verify the status and timeline of the BPH Phase II clinical trials and the submission of data to the FDA.
- Confirm the details and closing status of the private placement offering completed on January 9, 2002, and its impact on share dilution.
- Review the terms of the settlement agreement with the Stearns Parties, specifically the issuance of 6.3 million warrants at $0.01 per share.
- Assess the company's cash burn rate against the projected $7.5 million expenditure for the remainder of fiscal 2002.
- Monitor progress on the Investigational New Drug (IND) applications for the Doxorubicin-laden liposomes.